dc.contributor.advisor |
Maja, Todd Mamutle Mavis
|
|
dc.contributor.author |
Haumba, Samson Malwa
|
|
dc.date.accessioned |
2016-09-08T13:58:31Z |
|
dc.date.available |
2016-09-08T13:58:31Z |
|
dc.date.issued |
2015-06 |
|
dc.identifier.citation |
Haumba, Samson Malwa (2015) Best practice guidelines to monitor and prevent hearing loss related to drug resistant tuberculosis treatment, University of South Africa, Pretoria, <http://hdl.handle.net/10500/21189> |
en |
dc.identifier.uri |
http://hdl.handle.net/10500/21189 |
|
dc.description.abstract |
The purpose of the study was to develop best practice guidelines to prevent permanent hearing loss associated with the management of multi-drug resistant tuberculosis (MDR-TB) through raised awareness and monitoring. The Human Immunodeficiency Virus (HIV) and MDR-TB are global public health problems requiring urgent scale-up of treatment services. Irreversible sensorineural hearing loss (SNHL) is one of the adverse drug reactions of the current World Health Organization (WHO) recommended MDR-TB chemotherapy fuelling another public health problem, that disabling hearing loss, which is the second highest contributor of Years Lived with Disability (YLD) according to the World Health Report (2003). Expansion of MDR-TB treatment threatens to increase incidence of SNHL unless there is urgent implementation of intervention towards preservation of hearing for patients on treatment. This empirical study determined and documented the incidence of SNHL in HIV positive and HIV negative patients on MDR-TB treatment, the risk factors for SNHL, from the time treatment initiation to SNHL. Based on the findings, developed and improved the understanding of best practice guidelines for monitoring and prevention of MDR-TB treatment-related SNHL.
The empirical study recruited a cohort of 173 patients with normal hearing status, after diagnosis with MDR-TB and enrolled on MDR-TB therapy over thirteen month period. Patients in the cohort received monthly hearing sensitivity testing during the intensive MDR-TB therapy when injectable aminoglycoside antibiotics are part of the treatment regimen. The three study endpoints included completion of the eight-month intensive treatment phase without developing hearing loss, development incident hearing loss or loss to follow up. Data was analysed using STATA statistical software and summarised using frequencies, means, proportions, and rates. The study documented incidence of SNHL, time to hearing loss and risk factors for hearing loss. Recommendations to prevent and monitor hearing loss are made based on the the study findings. |
en |
dc.format.extent |
1 online resource (various pagings) : illustrations (some color) |
|
dc.language.iso |
en |
en |
dc.subject |
Sensorineural hearing loss |
en |
dc.subject |
Cochleotoxicity |
en |
dc.subject |
Multi drug resistant tuberculosis |
en |
dc.subject |
Aminoglycoside antibiotics |
en |
dc.subject |
Audiometry |
en |
dc.subject |
Incidence |
en |
dc.subject |
Time-to-event |
en |
dc.subject |
Best practice guidelines |
en |
dc.subject |
Prevention |
en |
dc.subject |
Monitoring |
en |
dc.subject.ddc |
610.730693096825 |
|
dc.subject.lcsh |
Deafness -- Prevention |
|
dc.subject.lcsh |
Tuberculosis -- Alternative treatment -- Swaziland |
|
dc.subject.lcsh |
Multidrug-resistant tuberculosis -- Treatment -- Swaziland |
|
dc.subject.lcsh |
Deaf -- Services for -- Swaziland |
|
dc.subject.lcsh |
Hearing clinics -- Management -- Swaziland |
|
dc.subject.lcsh |
Neuman systems model |
|
dc.subject.lcsh |
Public health -- Swaziland |
|
dc.title |
Best practice guidelines to monitor and prevent hearing loss related to drug resistant tuberculosis treatment |
en |
dc.type |
Thesis |
en |
dc.description.department |
Health Studies |
|
dc.description.degree |
D. Litt. et Phil. (Health Studies) |
|